- Home
- SEED vs INKT Comparison
SEED vs INKT Comparison
Compare SEED & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEED
- INKT
- Stock Information
- Founded
- SEED 1997
- INKT 2017
- Country
- SEED China
- INKT United States
- Employees
- SEED N/A
- INKT N/A
- Industry
- SEED Farming/Seeds/Milling
- INKT Medicinal Chemicals and Botanical Products
- Sector
- SEED Consumer Staples
- INKT Health Care
- Exchange
- SEED Nasdaq
- INKT Nasdaq
- Market Cap
- SEED 18.3M
- INKT 30.6M
- IPO Year
- SEED N/A
- INKT 2021
- Fundamental
- Price
- SEED $3.06
- INKT $0.70
- Analyst Decision
- SEED
- INKT Strong Buy
- Analyst Count
- SEED 0
- INKT 1
- Target Price
- SEED N/A
- INKT $9.00
- AVG Volume (30 Days)
- SEED 30.1K
- INKT 50.8K
- Earning Date
- SEED 11-01-2024
- INKT 11-07-2024
- Dividend Yield
- SEED N/A
- INKT N/A
- EPS Growth
- SEED N/A
- INKT N/A
- EPS
- SEED 1.21
- INKT N/A
- Revenue
- SEED $16,516,031.00
- INKT N/A
- Revenue This Year
- SEED N/A
- INKT N/A
- Revenue Next Year
- SEED N/A
- INKT N/A
- P/E Ratio
- SEED $2.37
- INKT N/A
- Revenue Growth
- SEED 64.93
- INKT N/A
- 52 Week Low
- SEED $1.37
- INKT $0.57
- 52 Week High
- SEED $6.38
- INKT $1.90
- Technical
- Relative Strength Index (RSI)
- SEED 49.63
- INKT 46.88
- Support Level
- SEED $2.82
- INKT $0.65
- Resistance Level
- SEED $3.11
- INKT $0.72
- Average True Range (ATR)
- SEED 0.20
- INKT 0.05
- MACD
- SEED -0.03
- INKT 0.00
- Stochastic Oscillator
- SEED 29.36
- INKT 71.61
About SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company. In crop seed biotechnologies, the company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.